Cargando…

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

BACKGROUND: Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Incorvaia, Lorena, Dimino, Alessandra, Algeri, Laura, Brando, Chiara, Magrin, Luigi, De Luca, Ida, Pedone, Erika, Perez, Alessandro, Sciacchitano, Roberta, Bonasera, Annalisa, Bazan Russo, Tancredi Didier, Li Pomi, Federica, Peri, Marta, Gristina, Valerio, Galvano, Antonio, Giuffrida, Dario, Fazio, Ivan, Toia, Francesca, Cordova, Adriana, Florena, Ada Maria, Giordano, Antonio, Bazan, Viviana, Russo, Antonio, Badalamenti, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149939/ https://www.ncbi.nlm.nih.gov/pubmed/37139149 http://dx.doi.org/10.3389/fonc.2023.1141500

Ejemplares similares

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement
por: Badalamenti, Giuseppe, et al.
Publicado: (2022)

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors
por: Dimino, Alessandra, et al.
Publicado: (2022)

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
por: Fanale, Daniele, et al.
Publicado: (2021)

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength
por: Fanale, Daniele, et al.
Publicado: (2022)

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer
por: Fanale, Daniele, et al.
Publicado: (2022)

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis
por: Norata, Davide, et al.
Publicado: (2023)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
por: Gristina, Valerio, et al.
Publicado: (2022)

Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
por: Grignani, Giovanni, et al.
Publicado: (2021)

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021)

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2022)

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge
por: Bono, M., et al.
Publicado: (2021)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
por: Fanale, Daniele, et al.
Publicado: (2020)

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
por: Galvano, Antonio, et al.
Publicado: (2020)

Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma
por: Buonerba, Luciana, et al.
Publicado: (2020)

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer
por: Fanale, Daniele, et al.
Publicado: (2023)

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
por: Galvano, Antonio, et al.
Publicado: (2020)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Re-Induction of Avelumab for Patients with Metastatic Merkel Cell Carcinoma
por: Hiroyuki, Goto, et al.
Publicado: (2023)

One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials
por: Galvano, Antonio, et al.
Publicado: (2019)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
por: Massihnia, Daniela, et al.
Publicado: (2016)

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1vi4j5obpnmu6s3adu1e4nnup4